Neither Amgen nor Johnson & Johnson could possibly have imagined three years ago that they would be registering oncologists in a program intended to curtail use of two blockbuster products, the erythropoiesis stimulating agents Aranesp (darbepoetin) and Procrit (epoetin).
But, after a long and difficult period of safety scrutiny, that is exactly what the companies are doing, thanks to...





